NCT00421980

An Open-Label, Multicentre, Long-Term Extension Study of Etanercept in Ankylosing Spondylitis

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 84 (planned)
• Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer · Industry
• Sex: All
• Age: 18 Years – 66 Years
• Healthy volunteers: Accepted

Summary

The primary objective of this study was to determine the long-term safety of etanercept in adults with AS who had completed study 0881A3-311-EU.

Detailed description

This was an open-label, multicenter extension study that was conducted to evaluate the safety and efficacy of etanercept in the treatment of adult subjects with AS who had completed study 0881A3-311-EU. The study consisted of an open-label treatment period of up to approximately 96 weeks.

Conditions

• Ankylosing Spondylitis

Interventions

Type	Name	Description
DRUG	Etanercept

Timeline

• Start date: 2002-06-01
• Completion: 2004-07-01
• First posted: 2007-01-15
• Last updated: 2007-01-15

Locations

1 site across 1 country: Belgium